Search of inhibitors of aldose reductase for treatment of diabetic cataracts using machine learning
- AOPR Vol. 3, Issue 4, Pages: 187-191(2023)
- 作者机构：
1. MAP Program, University of California, San Diego, La Jolla,CA,USA
2. San Diego Supercomputer Center, University of California, San Diego, La Jolla,CA,USA
3. CureScience Institute,CA,San Diego,USA
4. Department of Neurosciences, University of California, San Diego, La Jolla,CA,USA
- 作者简介：
- 基金信息：
DOI：10.1016/j.aopr.2023.09.002
CLC：
扫 描 看 全 文
Search of inhibitors of aldose reductase for treatment of diabetic cataracts using machine learning. [J]. AOPR 3(4):187-191(2023)
Search of inhibitors of aldose reductase for treatment of diabetic cataracts using machine learning. [J]. AOPR 3(4):187-191(2023) DOI： 10.1016/j.aopr.2023.09.002.
摘要
Purpose,Patients with diabetes mellitus have an elevated chance of developing cataracts, a degenerative vision-impairing condition often needing surgery. The process of the reduction of glucose to sorbitol in the lens of the human eye that causes cataracts is managed by the Aldose Reductase Enzyme (AR), and it is been found that AR inhibitors may mitigate the onset of diabetic cataracts. There exists a large pool of natural and synthetic AR inhibitors that can prevent diabetic complications, and the development of a machine-learning (ML) prediction model may bring new AR inhibitors with better characteristics into clinical use.,Methods,Using known AR inhibitors and their chemical-physical descriptors we created the ML model for prediction of new AR inhibitors. The predicted inhibitors were tested by computational docking to the binding site of AR.,Results,Using cross-validation in order to find the most accurate ML model, we ended with final cross-validation accuracy of 90%. Computational docking testing of the predicted inhibitors gave a high level of correlation between the ML prediction score and binding free energy.,Conclusions,Currently known AR inhibitors are not used yet for patients for several reasons. We think that new predicted AR inhibitors have the potential to possess more favorable characteristics to be successfully implemented after clinical testing. Exploring new inhibitors can improve patient well-being and lower surgical complications all while decreasing long-term medical expenses.
Abstract
Purpose,Patients with diabetes mellitus have an elevated chance of developing cataracts, a degenerative vision-impairing condition often needing surgery. The process of the reduction of glucose to sorbitol in the lens of the human eye that causes cataracts is managed by the Aldose Reductase Enzyme (AR), and it is been found that AR inhibitors may mitigate the onset of diabetic cataracts. There exists a large pool of natural and synthetic AR inhibitors that can prevent diabetic complications, and the development of a machine-learning (ML) prediction model may bring new AR inhibitors with better characteristics into clinical use.,Methods,Using known AR inhibitors and their chemical-physical descriptors we created the ML model for prediction of new AR inhibitors. The predicted inhibitors were tested by computational docking to the binding site of AR.,Results,Using cross-validation in order to find the most accurate ML model, we ended with final cross-validation accuracy of 90%. Computational docking testing of the predicted inhibitors gave a high level of correlation between the ML prediction score and binding free energy.,Conclusions,Currently known AR inhibitors are not used yet for patients for several reasons. We think that new predicted AR inhibitors have the potential to possess more favorable characteristics to be successfully implemented after clinical testing. Exploring new inhibitors can improve patient well-being and lower surgical complications all while decreasing long-term medical expenses.
关键词
Diabetic cataractsAldose reductase inhibitorMachine learningDeep learning
Keywords
Diabetic cataractsAldose reductase inhibitorMachine learningDeep learning
references
1 A. Singh Grewal, S. Bhardwaj, D. Pandita, et al.Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases Mini Rev Med Chem, 16 (2) (2016), pp. 120-162, 10.2174/1389557515666150909143737
2 L. Quattrini, C. La MottaAldose reductase inhibitors: 2013-present Expert Opin Ther Pat, 29 (3) (2019), pp. 199-213, 10.1080/13543776.2019.1582646
3 D.Z. Huang, V.L. Kouznetsova, I.F. TsigelnyDeep-learning-and pharmacophore-based prediction of RAGE inhibitors Phys Biol, 17 (3) (2020), Article 036003, 10.1088/1478-3975/ab6819
4 M.R. Gantla, I.F. Tsigelny, V.L. KouznetsovaRepurposing of drugs for combined treatment of COVID-19 cytokine storm using machine learning Med Drug Discov, 17 (2023), Article 100148, 10.1016/j.medidd.2022.100148
5 A. Gao, V.L. Kouznetsova, I.F. TsigelnyMachine-learning-based virtual screening to repurpose drugs for treatment of Candida albicans infection Mycoses, 65 (8) (2022), pp. 794-805, 10.1111/myc.13475
6 T. Sterling, J.J. IrwinZINC 15-ligand discovery for everyone J Chem Inf Model, 55 (11) (2015), pp. 2324-2337, 10.1021/acs.jcim.5b00559
7 C.W. YapPaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints J Comput Chem, 32 (7) (2011), pp. 1466-1474, 10.1002/jcc.21707
8 K. Hornik, C. Buchta, A. ZeileisOpen-source machine learning: R meets Weka Comput Stat, 24 (2009), pp. 225-232, 10.1007/s00180-008-0119-7
9 S. Dallakyan, A.J. OlsonSmall-molecule library screening by docking with PyRx Chem Biol: Methods Protoc (2015), pp. 243-250, 10.1007/978-1-4939-2269-7_19
10 N.M. O'Boyle, M. Banck, C.A. James, et al.Open Babel: an open chemical toolbox J Cheminf, 3 (1) (2011), pp. 1-4, 10.1186/1758-2946-3-33
11 D. Seeliger, B.L. de GrootLigand docking and binding site analysis with PyMOL and Autodock/Vina J Comput Aided Mol Des, 24 (5) (2010), pp. 417-422, 10.1007/s10822-010-9352-6
12 J.B. Kostis, J.M. DobrzynskiPrevention of cataracts by statins: a meta-analysis J Cardiovasc Pharmacol Therapeut, 19 (2) (2014), pp. 191-200, 10.1177/1074248413511690
13 J.M. Dobrzynski, J.B. KostisStatins and cataracts-a visual insight Curr Atherosclerosis Rep, 17 (2015), pp. 1-8, 10.1007/s11883-014-0477-2
14 P.H. Chou, C.S. Chu, C.H. Lin, et al.Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: a population-based, nested case-control study Schizophr Res, 174 (1-3) (2016), pp. 137-143, 10.1016/j.schres.2016.03.027
15 M. Dherani, G.V. Murthy, S.K. Gupta, et al.Blood levels of vitamin C, carotenoids and retinol are inversely associated with cataract in a North Indian population Invest Ophthalmol Vis Sci, 49 (8) (2008), pp. 3328-3335, 10.1167/iovs.07-1202
16 A.A. SmithPotentiation of opioid-Induced cataracts by catecholamines injected into the mouse brain Psychopharmacologia, 16 (1970), pp. 313-317, 10.1007/BF00404737
17 N. Cooper, R. Wong, A. Brainsky, et al.Rate of cataracts across the eltrombopag clinical studies in patients with chronic immune thrombocytopenia Blood, 118 (21) (2011), p. 1164, 10.1182/blood.V118.21.1164.1164
18 Y. Yang, J. Wu, W. Lu, et al.Olaparib, a PARP-1 inhibitor, protects retinal cells from ocular hypertension-associated oxidative damage Front Cell Dev Biol, 10 (2022), Article 925835, 10.3389/fcell.2022.925835
0
Views
0
下载量
0
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.